Free Shipping on Orders Over $149 — Lab-Tested 99%+ Purity — USA Shipped

GLP3-R (Retatrutide) 30mg - Research Peptide
Weight Management 30mg

GLP3-R (Retatrutide)

$399.00 In Stock

Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors for advanced metabolic studies.

≥98%
HPLC Purity
COA
Included
USA
Based Supplier

Description

Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors for advanced metabolic studies.

Retatrutide is a first-in-class triple-agonist peptide that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action involves binding all three receptor systems to modulate appetite signaling, glucose homeostasis, and energy expenditure through complementary metabolic pathways. In a phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving 12 mg of retatrutide achieved a mean body weight reduction of approximately 24.2% at 48 weeks, surpassing results observed with dual-agonist compounds like tirzepatide. The glucagon receptor component is believed to contribute additional energy expenditure and hepatic lipid metabolism benefits not seen with GLP-1-only or GIP/GLP-1 dual agonists. Compared to semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual), retatrutide represents an expansion of the incretin-based approach by incorporating glucagon receptor activation, which studies suggest enhances thermogenesis and fat oxidation. For research use, the lyophilized powder should be stored at -20C and reconstituted with bacteriostatic water immediately before use; reconstituted solutions remain stable under refrigeration at 2-8C for up to 28 days. This compound is primarily investigated by academic metabolic research centers, pharmaceutical R&D divisions, and endocrinology laboratories studying multi-receptor agonism as a strategy for metabolic syndrome research.

This product is supplied as a lyophilized powder and is intended for laboratory and research use only. Not for human consumption. Each vial contains 30mg of research-grade material.

Research Applications

  • GIP/GLP-1/Glucagon receptor agonist research
  • Obesity and metabolic disorder studies
  • Glucose regulation and insulin sensitivity
  • Body composition and weight management research

Specifications

Size
30mg
Purity
≥98% (HPLC)
Form
Lyophilized Powder
Molecular Formula
C223H343F3N46O70
Molecular Weight
4731.33 g/mol
CAS Number
2381089-83-2
Sequence
YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Storage & Handling

  • Long-term storage: -20°C in a sealed, light-protected container
  • Short-term storage: 2-8°C (refrigerated) for up to 30 days
  • Reconstituted: Store at 2-8°C and use within 30 days
  • Avoid: Repeated freeze-thaw cycles, direct sunlight, and moisture exposure
  • Reconstitution: Use bacteriostatic water or sterile water for injection

Frequently Asked Questions

What is GLP3-R (Retatrutide) and how does it work?
Retatrutide is a triple-agonist peptide that simultaneously targets GIP, GLP-1, and glucagon receptors. Unlike single- or dual-agonist compounds, retatrutide activates all three incretin and glucagon pathways, which in preclinical models has been observed to influence glucose homeostasis, energy expenditure, and lipid metabolism through complementary mechanisms. This tri-receptor engagement represents a novel approach in metabolic research.
What research has been done on GLP3-R (Retatrutide)?
Phase 2 clinical trial data published in the New England Journal of Medicine (2023) demonstrated that retatrutide produced significant reductions in body weight in study participants over 48 weeks. Preclinical studies have also explored its effects on hepatic lipid content, with researchers observing reductions in liver fat in animal models. Additional investigations are examining its potential role in non-alcoholic steatohepatitis (NASH) and cardiovascular biomarkers.
How does Retatrutide compare to Semaglutide or Tirzepatide?
While semaglutide acts solely on the GLP-1 receptor and tirzepatide targets both GIP and GLP-1 receptors, retatrutide adds a third mechanism through glucagon receptor agonism. In research settings, this triple-agonist approach has been associated with greater effects on energy expenditure and lipid oxidation compared to single- or dual-agonist peptides. Each compound occupies a distinct pharmacological profile for comparative metabolic research.
What is the recommended reconstitution protocol for Retatrutide?
For this 30mg vial, reconstitute with 3mL of bacteriostatic water to yield a concentration of 10mg/mL. Inject the water slowly along the inner wall of the vial — do not shake or agitate. Allow the lyophilized powder to dissolve fully (typically 2-5 minutes). Store reconstituted solution at 2-8°C and use within 30 days.
What purity testing is performed on Retatrutide?
Each batch of Retatrutide undergoes HPLC (High-Performance Liquid Chromatography) analysis to verify a minimum purity of 98%. Identity is confirmed via mass spectrometry (MS), and endotoxin levels are tested using the LAL method. A Certificate of Analysis (COA) documenting purity, molecular identity, peptide content, and residual solvent levels accompanies every batch.

Related Products

Cagrilintide 10mg
10mg In Stock

Cagrilintide

Long-acting synthetic amylin analogue for obesity and metabolic research.

$289.00
Tesamorelin 10mg
10mg In Stock

Tesamorelin

Synthetic GHRH analogue studied for visceral fat reduction and metabolic health.

$109.00
MOTS-C 40mg
40mg In Stock

MOTS-C

Mitochondrial-derived peptide for metabolic regulation and cellular energy research.

$175.00

Research Use Only. This product is not intended for human consumption, therapeutic use, or diagnostic purposes. All peptides sold by Elyte Peptides are strictly for in-vitro research and laboratory use. By purchasing, you agree to use this product in compliance with all applicable laws and regulations.